AniClin Provides Pharmacokinetic Studies in Less than 5 Days
AniClin Preclinical Services (“AniClin”), specializing in in vivo services to support early drug development activities, is now offering complete pharmacokinetic (PK) studies in less than five days. This quick turnaround service comes after entering a strategic alliance with Taylor Technology, a subsidiary of PharmaNet Development Group, which specializes in supporting bioanalytical programs of any size from Discovery to Phase IV.
The PK package offers formulation, dosing, PK sampling, bioanalysis (plasma) of 6 timepoints, inclusive of quality control samples and front and back standard curves, all in less than 5 days. AniClin and Taylor Technology work seamlessly to meet this Fast PK timeline which involves the NCE arriving at AniClin where dosing is performed and plasma samples are collected. The samples are then delivered to Taylor Technology within two hours. The plasma samples are immediately processed upon receipt for development of non-GLP bioanalytical protocols, data analysis and estimation of PK parameters. The data and PK estimates are then emailed to the sponsor.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
